ARK Genomic Revolution UCITS ETF Class A USD Accumulation GBP (ARCG.LSE) Stock Analysis & Winston Score

ARK Genomic Revolution UCITS ETF is a fund, not an operating company. It pools money from investors and uses it to buy shares in companies working on genomics and life sciences — things like DNA sequencing, gene editing, and personalized medicine. The fund is managed by ARK Invest and targets businesses trying to use biology and technology together to change how diseases are diagnosed and treated. The fund makes money by charging investors an annual management fee, taken as a percentage of the total assets held in the fund. It is listed on the London Stock Exchange in British pounds but invests globally, with a heavy focus on US-listed biotech and healthcare companies. The fund is actively managed, meaning ARK's team picks the stocks rather than just tracking an index. The main risk is that genomics companies are often early-stage, unprofitable, and sensitive to interest rate changes and regulatory decisions, making the fund more volatile than broad market funds.